

Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application

Listing of Claims:

1. - 24. (Canceled)
25. (Currently Amended) An isolated recombinant polypeptide comprising:
 - (a) the amino acid sequence SEQ ID NO:2 or
 - (b) an immunogenic fragment of ~~at least 15~~ or more contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject in a suitable composition, which can include an adjuvant or coupling to a suitable carrier, induces an antibody or T-cell mediated immune response that recognizes the polypeptide of SEQ ID NO:2.
26. (Canceled)
27. (Previously Presented) The isolated recombinant polypeptide of claim 25, wherein the polypeptide comprises the amino acid sequence SEQ ID NO:2.
28. (Canceled)
29. (Currently Amended) The isolated recombinant polypeptide of claim 25, wherein the polypeptide comprises an immunogenic fragment of ~~at least 15~~ or more contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or coupling to a suitable carrier, induces an antibody or T-cell mediated immune response that recognizes the polypeptide of SEQ ID NO:2.
30. (Canceled)
31. (Currently Amended) The isolated recombinant polypeptide of claim 25, wherein the immunogenic fragment of (b) comprises ~~at least 20~~ or more contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition, which can include an adjuvant or coupling to a suitable carrier, induces an antibody or T-cell mediated immune response that recognizes the polypeptide of SEQ ID NO:2.

32. (Previously Presented) The isolated recombinant polypeptide of claim 25, wherein the isolated recombinant polypeptide consists of SEQ ID NO:2.

33. (Canceled)

34. (Canceled)

35. (Previously Presented) An isolated recombinant fusion protein comprising the polypeptide of claim 25.

36. - 39. (Canceled)

40. (Previously Presented) An immunogenic composition comprising the recombinant polypeptide of claim 25 and a pharmaceutically acceptable carrier.

41. (Previously Presented) The immunogenic composition of claim 40, wherein the immunogenic composition comprises at least one other *Neisseria meningitidis* antigen.

42. (Canceled)

43. (Previously Presented) A method for inducing an immune response in a mammal comprising administration of the isolated recombinant polypeptide of claim 25.

44. - 47. (Canceled)

48. (Previously Presented) An isolated recombinant fusion protein comprising the polypeptide of claim 27.

49. (Previously Presented) An immunogenic composition comprising the isolated recombinant polypeptide of claim 27.

50. (Previously Presented) An isolated recombinant fusion protein comprising the polypeptide of claim 29.

51. (Previously Presented) An immunogenic composition comprising the isolated recombinant polypeptide of claim 29.

52. - 56. (Canceled)

57. (Previously Presented) An isolated recombinant fusion protein comprising polypeptide of claim 31.

58. (Previously Presented) An immunogenic composition comprising the isolated recombinant polypeptide of claim 25.

59. (Previously Presented) An immunogenic composition comprising the isolated recombinant polypeptide of claim 31.